# O-demethyl galantamine alters protein expression in cerebellum of 5xFAD mice

**Authors:** İrem KIRIŞ, Merve KARAYEL BAŞAR, Büşra GÜREL, Tomasz MROCZEK, Ahmet Tarık BAYKAL

PMC · DOI: 10.55730/1300-0152.2692 · Turkish Journal of Biology · 2024-05-28

## TL;DR

This study explores how O-demethyl galantamine affects protein expression in the cerebellum of Alzheimer's mice, suggesting potential for combination therapies.

## Contribution

The study reveals that O-demethyl galantamine specifically alters cerebellar protein expression in a mouse model of Alzheimer's disease.

## Key findings

- O-demethyl galantamine (ODG) significantly altered protein expression in the cerebellum of 5xFAD mice.
- Ras signaling and retrograde endocannabinoid signaling pathways were enriched in ODG-treated mice.
- GNB1, GNB2, NDUFS6, PAK2, and RhoA were identified as top hub proteins in the cerebellum of ODG-treated mice.

## Abstract

Alzheimer’s disease (AD), one of the most common health issues, is characterized by memory loss, severe behavioral disorders, and eventually death. Despite many studies, there are still no drugs that can treat AD or stop it from progressing. Previous in vitro tests showed that O-demethyl galantamine (ODG) might have therapeutic potential owing to its 10 times higher acetylcholinesterase inhibitory activity than galantamine (GAL).

We aimed to assess the effect of ODG at the molecular level in a 12-month-old 5xFAD Alzheimer’s mouse model. To this end, following the administrations of ODG and GAL (used as a positive control), protein alterations were investigated in the cortex, hippocampus, and cerebellum regions of the brain. Surprisingly, GAL altered proteins prominently in the cortex, while ODG exclusively exerted its effect on the cerebellum.

GNB1, GNB2, NDUFS6, PAK2, and RhoA proteins were identified as the top 5 hub proteins in the cerebellum of ODG-treated mice. Reregulation of these proteins through Ras signaling and retrograde endocannabinoid signaling pathways, which were found to be enriched, might contribute to reversing AD-induced molecular changes.

We suggest that, since it targets specifically the cerebellum, ODG may be further evaluated for combination therapies for AD.

## Linked entities

- **Proteins:** GNB1 (G protein subunit beta 1), GNB2 (G protein subunit beta 2), NDUFS6 (NADH:ubiquinone oxidoreductase subunit S6), PAK2 (p21 (RAC1) activated kinase 2), RHOA (ras homolog family member A)
- **Chemicals:** galantamine (PubChem CID 9651)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** Ndufs6 (NADH:ubiquinone oxidoreductase core subunit S6) [NCBI Gene 407785] {aka IP13}, Rhoa (ras homolog family member A) [NCBI Gene 11848] {aka Arha, Arha1, Arha2}, Gnb1 (guanine nucleotide binding protein (G protein), beta 1) [NCBI Gene 14688] {aka Gnb-1, Hg2a}, Ache (acetylcholinesterase) [NCBI Gene 11423], Pak2 (p21 (RAC1) activated kinase 2) [NCBI Gene 224105] {aka 5330420P17Rik, A130002K10Rik, D16Ertd269e, PAK-2, mKIAA4182}, Gnb2 (guanine nucleotide binding protein (G protein), beta 2) [NCBI Gene 14693] {aka Gnb-2, Hg2c1}
- **Diseases:** behavioral disorders (MESH:D001523), memory loss (MESH:D008569), death (MESH:D003643), AD (MESH:D000544)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11265889/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11265889/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC11265889/full.md

---
Source: https://tomesphere.com/paper/PMC11265889